Conference Coverage
Alirocumab sharply reduced major cardiovascular events
Key clinical point: The lower-is-better approach to LDL reduction gets a big boost from a study that showed adding alirocumab to maximally...
CHICAGO – Discussant Dr. Robert M. Califf called the results of the ODYSSEY LONG TERM trial presented by Dr. Jennifer G. Robinson at the annual congress of the European Society of Cardiology "alluring" and "fantastic," with a reported 54% reduction in major adverse cardiovascular events in high-risk, statin-treated patients on add-on alirocumab. But neither he nor Dr. Robinson consider these results to be the final word on the subject.
Here’s what Dr. Robinson had to say about the investigational PCSK9 inhibitor’s performance in the study.